Form 8-K - Current report:
SEC Accession No. 0001104659-24-071249
Filing Date
2024-06-13
Accepted
2024-06-13 16:05:16
Documents
14
Period of Report
2024-06-13
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2417220d1_8k.htm   iXBRL 8-K 41286
2 EXHIBIT 3.1 tm2417220d1_ex3-1.htm EX-3.1 11902
  Complete submission text file 0001104659-24-071249.txt   235338

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA trda-20240613.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE trda-20240613_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trda-20240613_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2417220d1_8k_htm.xml XML 3924
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

EIN.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40969 | Film No.: 241041211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)